877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Mu-opioid agonists, Antidepressants

Categories

Analgesics (8)
Dissociative drugs (8)
Drugs acting on the nervous system (8)
Euphoriants (8)
Kappa agonists (8)
Opioid receptor ligands (8)
Opioids (8)
Psychoactive drugs (8)
Psychopharmacology (8)
Delta-opioid agonists (7)
Drugs acting on the respiratory system (7)
GABA receptor antagonists (7)
GABA receptor ligands (7)
Monoamine reuptake inhibitors (7)
Nociceptin receptor agonists (7)
Respiratory system drug (7)
Serotonin-norepinephrine reuptake inhibitors (7)
Synthetic opioids (7)
Antianginals (4)
Antiarrhythmic agents (4)
Antihypertensive agents (4)
Calcium channel blockers (4)
Drugs acting on the cardiovascular system (4)
Analgesic (3)
Semisynthetic opioids (3)
Pharmaceuticals (2)
Amines (1)
Anesthetics (1)
Bases (chemistry) (1)
General anesthetics (1)
Ketones (1)
Psychoanaleptics (1)

Suppliers

Sigma Aldrich (2)

Levomethorphan (510-53-2, 125-71-3, 125-70-2)  
Dextromethorphan  ·  Dextromethorphan Hydrobromide  ·  Delsym
Methorphan comes in two isomeric forms, each with differing pharmacology and effects: Dextromethorphan - An over-the-counter cough suppressant, as well as dissociative hallucinogen. Levomethorphan - A potent opioid analgesic that was never clinically developed; the codeine analogue of the powerful opioid agonist analgesic levorphanol (Levo-Dromoran). Racemethorphan refers to the racemic mixture of both of these stereoisomers.
dextromethorphan (510-53-2, 125-71-3, 125-70-2)  
Dextromethorphan Hydrobromide  ·  Delsym  ·  Levomethorphan
Methorphan comes in two isomeric forms, each with differing pharmacology and effects: Dextromethorphan - An over-the-counter cough suppressant, as well as dissociative hallucinogen. Levomethorphan - A potent opioid analgesic that was never clinically developed; the codeine analogue of the powerful opioid agonist analgesic levorphanol (Levo-Dromoran). Racemethorphan refers to the racemic mixture of both of these stereoisomers.
levorphanol (77-07-6, 297-90-5)  
Levorphanol Tartrate  ·  Levorphan  ·  LevoDromoran
Levorphanol (INN; brand name Levo-Dromoran) is an opioid medication used to treat moderate to severe pain. It is one of four enantiomers of the compound racemorphan, and was first described in Germany in 1948 as an orally active, morphine-like analgesic. The drug has been in clinical use in the United States since 1953.
DEXTRORPHAN (297-90-5, 125-73-5)  
(+-)-17-Methylmorphinan-3-ol
Dextrorphan (DXO) is a psychoactive drug of the morphinan class which acts as an antitussive or cough suppressant and dissociative hallucinogen. It is the dextrorotatory-stereoisomer of racemorphan, the levo-half being levorphanol. Dextrorphan is produced by O-demethylation of dextromethorphan by CYP2D6.
norketamine (35211-10-0)  
Norketamine, or N-desmethylketamine, is the major active metabolite of ketamine, which is formed mainly by CYP3A4. Similarly to ketamine, norketamine acts as a noncompetitive NMDA receptor antagonist (Ki = 1.7 µM and 13 µM for (S)-(+)-norketamine and (R)-(–)-norketamine, respectively), but is about 3–5 times less potent as an anesthetic in comparison. Also, similarly again to ketamine, norketamine binds to the μ- and κ-opioid receptors.
Racemorphan (297-90-5)  
Racemorphan, or morphanol, is the racemic mixture of the two stereoisomers of 17-methylmorphinan-3-ol, each with differing pharmacology and effects: Dextrorphan - an antitussive and dissociative hallucinogen (NMDA receptor antagonist) Levorphanol - an opioid analgesic Racemorphan itself is under international control per the Single Convention on Narcotic Drugs 1961 and is therefore listed as a Schedule II Narcotic controlled substance in the US Controlled Substances Act 1970; it has an ACSCN of 9733 and in 2014 it had an aggregate annual manufacturing quota of zero. The salts in use are hydrobromide (free base conversion ratio 0.741), hydrochloride (0.876), and tartrate (0.632).
125-73-5 (125-73-5)  
Dextrorphan (DXO) is a psychoactive drug of the morphinan class which acts as an antitussive or cough suppressant and dissociative hallucinogen. It is the dextrorotatory-stereoisomer of racemorphan, the levo-half being levorphanol. Dextrorphan is produced by O-demethylation of dextromethorphan by CYP2D6.

Related Results:
Agomelatine (138112-76-2)  
Agomelatine (brand names Valdoxan, Melitor, Thymanax) is an atypical antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder, primarily for its relatively favorable side effect profile: it avoids the weight gain, sexual dysfunction, and severe withdrawal associated with the most commonly used classes of antidepressants (SSRIs, SNRIs, tricyclics), while providing similar therapeutic benefit. Due to its distinctive mechanism of action, agomelatine is also studied for its effects on sleep regulation.
mianserin (78684-63-6, 24219-97-4)  
Mianserin Hydrochloride  ·  Org GB 94  ·  Tolvon
Mianserin, sold under the brand name Tolvon among others, is an atypical antidepressant which is used in the treatment of depression in Europe and elsewhere in the world. It is a tetracyclic antidepressant (TeCA). Mianserin is closely related to mirtazapine, both chemically and in terms of its actions and effects, although there are significant differences between the two drugs.
TETRABENAZINE (58-46-8)  
Nitoman  ·  Orphan Brand of Tetrabenazine  ·  Tetrabenazine Orphan Brand
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand, some parts of Europe and in the United States as an orphan drug. On August 15, 2008, the U.S.
amisulpride (71675-85-9, 53583-79-2)  
Solian  ·  sultopride  ·  DAN 2163
Amisulpride, sold under the brand name Solian among others, is an antipsychotic medication used to treat schizophrenia. In Italy, at a lower dosage of 50 mg per day, it is also used as a treatment for dysthymia. It is usually classed with the newer generation of antipsychotics, the so called atypical antipsychotics.
INDORAMIN (26844-12-2)  
Wy 21901  ·  Wy-21901  ·  Wy21901
Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent. It is an alpha-1 selective adrenoceptor antagonist with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).
Dexpramipexole (104632-28-2)  
Dexpramipexole (KNS-760704) is a drug that was investigated by Knopp Biosciences and Biogen Idec for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. More recently, dexpramipexole was shown in a Phase 2 open-label trial to reduce eosinophil counts and eliminate the need for corticosteroid treatment in a subset of patients with steroid-responsive hypereosinophilic syndrome.
Milnacipran (92623-85-3, 96847-55-1)  
Milnacipran (trade names Ixel, Savella, Dalcipran, Toledomin) is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia. It is not approved for the clinical treatment of major depressive disorder in the USA, but it is in other countries.
Brofaromine (63638-91-5)  
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.
citalopram hydrobromide (59729-32-7)  
Citalopram (brand names: Celexa, Cipramil and others) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has U.S. Food and Drug Administration approval to treat major depression, which it received in 1998, and is prescribed off-label for other conditions.
Esmirtazapine (61337-87-9)  
mirtazapine  ·  Remeron  ·  Rexer
Esmirtazapine (ORG-50,081) is a drug which was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors. As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.
ritanserin (87051-43-2)  
Ritanserin (INN, USAN, BAN) is a serotonin receptor antagonist which was never marketed for clinical use but has been used in scientific research.
Related searches
Mu-opioid agonists
Antidepressants
Next Page >